Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 7, 2019; 25(9): 1142-1157
Published online Mar 7, 2019. doi: 10.3748/wjg.v25.i9.1142
Published online Mar 7, 2019. doi: 10.3748/wjg.v25.i9.1142
Study | Intervention | Comparator | Follow-up | n | Clinical response, RR (95%CI) or OR (95%CI) | Quality of evidence |
Komaki et al[28] | Tacrolimus | Placebo | 2 wks (RCT) | 103 | RR 4.61 (2.09-10.17)1 | High |
Baumgart et al[25] | Tacrolimus | Placebo | 2 wk | 63 | OR 8.66 (1.79-42.00)2 | High |
Lasa et al[26] | Tacrolimus | Placebo | 12 wk | 127 | RR 0.58 (0.45-0.73)3 | High |
Narula et al[29] | IFX | Cyclosporine | 3 mo (RCT) | 412 | 43.8% (IFX); 41.7% (C) OR 1.08 (0.73-1.60)4 | Low |
IFX | Cyclosporine | 3 mo (non RCT) | 801 | 74.8% (IFX); 55.4% (C) OR 2.96 (2.12-4.14)5 | Very low |
- Citation: Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157
- URL: https://www.wjgnet.com/1007-9327/full/v25/i9/1142.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i9.1142